🇺🇸 FDA
Pipeline program

VGX-3100

HPV-201

Phase 2 mab completed

Quick answer

VGX-3100 for Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) is a Phase 2 program (mab) at INOVIO PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
INOVIO PHARMACEUTICALS, INC.
Indication
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials